The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | The importance of genomic testing in the diagnosis of CLL
Michel van Gelder, MD, PhD, Maastricht University, Maastricht, Netherlands, discusses the importance of genomic testing as a diagnostic tool for chronic lymphocytic leukemia (CLL), including identifying IGHV mutations and TP53 abnormalities, as this provides key information about life expectancy and which therapeutic route to take. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
